drugset

drugset / Trial / NCT00754104

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

NCT00754104 ↗

Phase 1 Withdrawn Abbott Genentech, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors

Timeline

Start: 2008-09
Primary completion: 2008-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABT-869	Unknown	0.25 mg/kg	—
Subject	Erlotinib	Small molecule	150 mg	—

Indications